Skip to main
RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast & Price Target

Reviva Pharmaceuticals (RVPH) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Reviva Pharmaceuticals Holdings Inc. is poised for a positive outlook as its lead drug candidate, Brilaroxazine, has shown robust treatment benefits in multiple neuropsychiatric indications, particularly in schizophrenia, with statistically significant improvements demonstrated across phase I, II, and III studies. The sustained efficacy, including an 18-point decrease in PANSS scores over one year and significant reductions in all major symptom domains, positions the drug favorably for clinical advancement and potential commercialization. Additionally, the company's commitment to continuing clinical trials, including a confirmatory Phase 3 study as recommended by the FDA, further supports the development of Brilaroxazine and may enhance investor confidence in the company's long-term financial prospects.

Bears say

Reviva Pharmaceuticals Holdings Inc's stock outlook has turned negative due to the company's announcement of a 1-for-20 reverse stock split, which typically indicates underlying financial distress and can result in reduced liquidity and weakened shareholder confidence. The company's pipeline faces significant risks, including the potential inability to successfully complete pivotal trials for its lead drug candidate, Brilaroxazine, as well as challenges related to patent protections, which can adversely affect market success and valuation. Additionally, the likelihood of negative trial data and failure to secure commercial partnerships raises concerns about the company's ability to achieve sustainable revenue growth, contributing to an unfavorable financial outlook.

Reviva Pharmaceuticals (RVPH) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Reviva Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Reviva Pharmaceuticals (RVPH) Forecast

Analysts have given Reviva Pharmaceuticals (RVPH) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Reviva Pharmaceuticals (RVPH) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Reviva Pharmaceuticals (RVPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.